Suggested remit: To appraise the clinical and cost effectiveness of gosuranemab within its marketing authorisation for treating progressive supranuclear palsy.
- Status:
- Awaiting development
- Decision:
- None selected
- Process:
- TA
- ID number:
- 1607
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 December 2019 | The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of gosuranemab for treating progressive supranuclear palsy. NICE recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal. The company that market gosuranemab has advised NICE that they are no longer pursuing a licence in the UK for this product for this indication. In light of this information NICE will not be progressing with the scoping exercise. Consequently the scoping workshop arranged for Wednesday 15 January 2020 will be cancelled. If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar at [email protected] |
For further information on our processes and methods, please see our CHTE processes and methods manual